|
21 Companies |
|
19 Products |
|
19 Products |
|
23 Mechanisms of Action |
|
0 Trials |
|
101 News |
|
| «123» |
- Trial completion: Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) (clinicaltrials.gov) - May 5, 2014
P2, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P1/2 trial: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Apr 26, 2014
P1/2, N=4, Not yet recruiting, Sponsor: James Chodosh, MD, MPH
- cyclophosphamide / Generic mfg.
Trial termination: Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus (clinicaltrials.gov) - Apr 10, 2014
P2, N=24, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Completed Recruiting --> Terminated; Study was terminated due to the death of the PI.
- Trial withdrawal: Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Terminated; Study was terminated due to the death of the PI. Recruiting --> Withdrawn
- Trial suspension: Multidrug Blister Pack Study (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=200, Suspended, Sponsor: Kurt Hersberger
Recruiting --> Withdrawn Recruiting --> Suspended
- Enrollment open: DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=420, Recruiting, Sponsor: Centre hospitalier de l'Universit
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Tyrisa (darapladib) / GSK
Enrollment open, IO biomarker: Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Mar 5, 2014
P1, N=16, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | cyclophosphamide / Generic mfg.
Trial completion: Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus (clinicaltrials.gov) - Feb 19, 2014
P2, N=35, Completed, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- | Tyrisa (darapladib) / GSK
New P1 trial, IO biomarker: Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Feb 6, 2014
P1, N=16, Recruiting, Sponsor: GlaxoSmithKline
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=5, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- Trial completion: Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=10, Completed, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial termination: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Nov 19, 2013
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
Recruiting --> Completed Active, not recruiting --> Terminated
- Enrollment open, IO biomarker: Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=130, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- ||||||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion: Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids (clinicaltrials.gov) - Oct 14, 2013
P3, N=56, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Oct 3, 2013
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
Recruiting --> Completed N=21 --> 1
- Enrollment open: Visual Distraction as a Means of Enhancing Child Resistance (clinicaltrials.gov) - Aug 26, 2013
P=N/A, N=500, Recruiting, Sponsor: Michigan State University
N=21 --> 1 Not yet recruiting --> Recruiting
- New P1 trial: Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jul 23, 2013
P1, N=6, Completed, Sponsor: Royan Institute
- Trial completion: Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jul 23, 2013
P1, N=6, Completed, Sponsor: Royan Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- timbetasin topical (RGN-137) / RegeneRx
Trial initiation date: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 6, 2013
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
Not yet recruiting --> Completed Initiation date: Jan 2005 --> Feb 2006
- Trial withdrawal: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 19, 2013
P=N/A, N=0, Withdrawn, Sponsor: Lotus Tissue Repair, Inc.
Initiation date: Jan 2005 --> Feb 2006 Not yet recruiting --> Withdrawn
- Enrollment change: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 19, 2013
P=N/A, N=0, Withdrawn, Sponsor: Lotus Tissue Repair, Inc.
Not yet recruiting --> Withdrawn N=80 --> 0
- | ligelizumab (QGE 031) / Novartis
Enrollment open: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - May 1, 2013
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
N=80 --> 0 Not yet recruiting --> Recruiting
- Nucala (mepolizumab) / GSK
Trial initiation date: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - May 1, 2013
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Feb 2013
- Nucala (mepolizumab) / GSK
Enrollment open: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - May 1, 2013
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne
Initiation date: Nov 2012 --> Feb 2013 Not yet recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial withdrawal: Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) (clinicaltrials.gov) - Apr 24, 2013
P2, N=0, Withdrawn, Sponsor: Loyola University
Not yet recruiting --> Recruiting Terminated --> Withdrawn
- Remicade (infliximab) / J&J
Trial completion: Use of Infliximab for the Treatment of Pemphigus Vulgaris (clinicaltrials.gov) - Jan 30, 2013
P2, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Terminated --> Withdrawn Active, not recruiting --> Completed
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Dec 17, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- mitomycin / Generic mfg.
Trial completion: SDOCT-TE: Imaging of Trabeculectomy Blebs Using the Spectral Domain Optical Coherence Tomography (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=30, Completed, Sponsor: Dresden University of Technology
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=1, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed N=34 --> 1
- New P3 trial: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Dec 11, 2012
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
- Trial completion: Study of Alwextin® Cream in Treating Epidermolysis Bullosa (clinicaltrials.gov) - Nov 28, 2012
P2, N=8, Completed, Sponsor: Northwestern University
N=34 --> 1 Active, not recruiting --> Completed
- Nucala (mepolizumab) / GSK
New P2 trial: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Oct 10, 2012
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (clinicaltrials.gov) - Oct 8, 2012
P3, N=20, Recruiting, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Sep 27, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- | ligelizumab (QGE 031) / Novartis
New P2 trial: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - Sep 18, 2012
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab in the Treatment of Patients With Bullous Pemphigoid (clinicaltrials.gov) - Sep 18, 2012
P1/2, N=8, Completed, Sponsor: Duke University
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial initiation date: Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab (clinicaltrials.gov) - Sep 11, 2012
P3, N=22, Completed, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Initiation date: Jun 2010 --> Jun 2011
- Filsuvez (AP101) / Amryt
Trial completion: Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10) (clinicaltrials.gov) - Jul 9, 2012
P2, N=10, Completed, Sponsor: Birken AG
Initiation date: Jun 2010 --> Jun 2011 Recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial completion: Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab (clinicaltrials.gov) - Jun 21, 2012
P3, N=22, Completed, Sponsor: University Hospital, Rouen
Recruiting --> Completed Recruiting --> Completed
- | New P4 trial: A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 12, 2012
P4, N=18, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- Trial withdrawal: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
Not yet recruiting --> Withdrawn N=10 --> 0
- cyclophosphamide / Generic mfg.
Trial termination: Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders (clinicaltrials.gov) - Apr 8, 2012
P1, N=1, Terminated, Sponsor: Richard Burt, MD
N=10 --> 0 Recruiting --> Terminated; sponsor stopped the study because of lack of elligible participants
- cyclophosphamide / Generic mfg.
Enrollment change: Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders (clinicaltrials.gov) - Apr 8, 2012
P1, N=1, Terminated, Sponsor: Richard Burt, MD
Recruiting --> Terminated; sponsor stopped the study because of lack of elligible participants N=20 --> 1
- New P2 trial: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Feb 6, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
- Trial termination: Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=20 --> 1 Recruiting --> Terminated; Competing studies
- Enrollment change: Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated; Competing studies N=30 --> 7
- timbetasin topical (RGN-137) / RegeneRx
Trial termination: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jan 25, 2012
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
N=30 --> 7 Completed --> Terminated; Lack of patient availability and expiration of study drug